The results of the ABSORB III trial were within the prespecified margin for noninferiority with regards to the primary end point of target-lesion failure, which researchers defined as cardiac death, target-vessel MI or ischemia-driven target-lesion revascularization.

Within two years following PCIs, 13.3 percent of subsequent scheduled noncardiac surgical procedures were cancelled, according to an analysis of all PCIs performed at the Veterans Affairs (VA) Healthcare System from fiscal year 2000 to 2010.

From Oct. 11 to 15, leaders in interventional cardiovascular medicine will gather in San Francisco for the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Cardinal Health completed its acquisition of Johnson and Johnson’s Cordis business on Oct. 4 for $1.944 billion, seven months after Cardinal Health announced its offer.

The FDA granted a 510(k) clearance on Oct. 6 to the CorPath System for use during PCIs performed via radial access.

For the past few years, the Transcatheter Cardiovascular Therapeutic (TCT) conference has focused on structural heart disease as a major subspecialty in interventional cardiology. This year’s conference, which runs from Oct. 10 to 15 in San Francisco, will have more of an emphasis on coronary intervention, according to TCT co-director Gregg W. Stone, MD.

The FDA approved the Synergy bioabsorbable polymer drug-eluting stent system on Oct. 5 to treat coronary artery disease. The Synergy stent is the first FDA-approved bioabsorbable polymer drug-eluting stent system, according to Boston Scientific, its manufacturer. The stent was approved in Europe in 2012.

Problems put off are problems exacerbated. In life and health, we need to study and address problems to find solutions.